OS increased by 476,740 to 330,333,853 as of 1 July. I wonder if this was issued to convertible notes or something else. ALPS has continually been on the ask this week with minimal lot size.

As far as increased burn rate, I agree that it may increase slightly. Based on NPs estimate of $28-30M if this is for rest of 2019 (6 months) less convertible notes (he said these were in addition to these amounts) and the milestone payments due to Progentics ($5M upon approval) and Abbvie ($500K upon BLA filing) this = burn rate of $3.75M-$4.1M/month. If NP timeline meant combo approval and assuming worst case of 9 months (March 2020) this would be as little as $2.5M/month. I lean to the end of 2019 burn rate of ~$4M/month with everything going on. Let's have some great news soon and a good 2nd public TO to get closer to required cash.

I expect some institutional investment once the warrants are cleaned up. IMO, this TO is to bring in needed cash AND specifically clean up warrants for future institutional investment. Once warrants are resolved we will have enough funding for trials and day-to-day operations to get to approval, but will still need cash for commercialization, distribution and marketing. NP has stated that large institutions said they would finance us and not to license with Gilead.....or maybe the offers will increase and they will license out certain indications? Time will tell, but I can envision things playing out either way....and both avenues should have great impacts on the share price.